Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial Read more about Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603 Read more about Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial Read more about Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update Read more about Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering Read more about Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market Read more about Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring Read more about Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum to Participate in Two Upcoming Virtual Conferences Read more about Bellicum to Participate in Two Upcoming Virtual Conferences
Bellicum to Participate in Two Upcoming Virtual Investor Conferences Read more about Bellicum to Participate in Two Upcoming Virtual Investor Conferences